Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,108 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,001)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03935893 | Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers | active not recruiting | Phase 2 | 20 | Udai KammulaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05507632 | Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma | active not recruiting | Phase 2 | 48 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06465563 | SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer | active not recruiting | Phase 2 | 93 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT03598998 | Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas | active not recruiting | Phase 1 / Phase 2 | 13 | City of Hope Medical CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT03548961 | Organ Preservation in Early Rectal Cancer Patients | active not recruiting | Phase 2 | 19 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04196465 | Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers(NeoChance) | active not recruiting | Phase 2 | 48 | Asan Medical CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04494009 | PD-1 Inhibitor INCMGA00012 as Consolidation Therapy After Definitive Concurrent Chemoradiotherapy(RHAPSODY) | active not recruiting | Phase 2 | 110 | Asan Medical CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04503694 | Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer(REGINA) | active not recruiting | Phase 2 | 72 | Jules Bordet InstituteOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07587619 | Intraoperative Use of Oxygen Saturation Imaging to Assess Intestinal Perfusion | active not recruiting | Phase 1 / Phase 2 | 52 | University of Southern CaliforniaOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07173387 | Stereotactic Body Radiotherapy and NALIRIFOX for Locally Advanced Pancreatic Cancer(RAD-NALIRIFOX) | active not recruiting | Phase 2 | 42 | Shandong Cancer Hospital and InstituteOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07280377 | A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab(GOBLET) | active not recruiting | Phase 1 / Phase 2 | 122 | Oncolytics BiotechINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT03386500 | Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer | active not recruiting | Phase 1 / Phase 2 | 24 | University of NebraskaOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT04042831 | Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations | active not recruiting | Phase 2 | 32 | Academic and Community Cancer Research UnitedOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT06251973 | A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer | active not recruiting | Phase 2 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT04589234 | Saltikva for Metastatic Pancreatic Cancer | active not recruiting | Phase 2 | 60 | Salspera LLCINDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT05988918 | Multicenter Trial of ESK981 in Patients With Select Solid Tumors | active not recruiting | Phase 2 | 17 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07241715 | Conversion Surgery for Gastric Cancer With Peritoneal Metastases (CONVERGENCE)(CONVERGENCE) | active not recruiting | Phase 2 / Phase 3 | 300 | National University Hospital, SingaporeOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07081633 | Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma(TREMENDOUS-2) | active not recruiting | Phase 2 | 114 | AstraZenecaINDUSTRY | 2 | May 12, 2026 | clinicaltrials |
| NCT04331041 | Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma | active not recruiting | Phase 2 | 42 | Washington University School of MedicineOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT05694936 | Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer | active not recruiting | Phase 2 | 38 | Australasian Gastro-Intestinal Trials GroupNETWORK | 1 | May 8, 2026 | clinicaltrials |
| NCT01840592 | Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib | active not recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT03523312 | Use of High-dose Radiation Therapy Plus Chemotherapy to Improve the Likelihood of Surgical Treatment in Patients With Locally Advanced Pancreatic Cancer(MAIBE) | active not recruiting | Phase 2 | 47 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06094140 | NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer(NEO-IMPACT) | active not recruiting | Phase 2 | 20 | Australasian Gastro-Intestinal Trials GroupNETWORK | 1 | May 6, 2026 | clinicaltrials |
| NCT03107416 | Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells | active not recruiting | Phase 1 / Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03482102 | Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer | active not recruiting | Phase 2 | 37 | Massachusetts General HospitalOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05933265 | Study of LP-184 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 64 | Lantern Pharma Inc.INDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT05961709 | The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer | active not recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT06015659 | ZN-c3 + Gemcitabine in Pancreatic Cancer | active not recruiting | Phase 2 | 12 | Brandon Huffman, MDOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT07138885 | A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma(DRIVE-II) | active not recruiting | Phase 2 | 62 | Sun Yat-sen UniversityOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06045975 | Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by by Percutaneous Ablation Procedure(DUMELEP) | active not recruiting | Phase 2 | 30 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03682289 | Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors | active not recruiting | Phase 2 | 83 | Rahul AggarwalOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06864169 | A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)(REJOICE-GI01) | active not recruiting | Phase 2 | 160 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Apr 23, 2026 | clinicaltrials |
| NCT05480384 | Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction | active not recruiting | Phase 2 | 1 | Brown UniversityOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT02713269 | Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord | active not recruiting | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04725994 | Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer | active not recruiting | Phase 1 / Phase 2 | 87 | Idience Co., Ltd.INDUSTRY | 3 | Apr 17, 2026 | clinicaltrials |
| NCT06777316 | A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 110 | Cogent Biosciences, Inc.INDUSTRY | 2 | Apr 17, 2026 | clinicaltrials |
| NCT07523763 | Neoadjuvant Low-dose Immunotherapy in Locally Advanced MMR-deficient Colorectal Cancer(NIVO1002024) | active not recruiting | Phase 2 | 30 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT03157128 | A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)(LIBRETTO-001) | active not recruiting | Phase 1 / Phase 2 | 857 | Eli Lilly and CompanyINDUSTRY | 16 | Apr 16, 2026 | clinicaltrials |
| NCT04940286 | Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer | active not recruiting | Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT01512589 | Proton Beam Therapy (PBT) Versus Intensity-Modulated Radiation Therapy (IMRT) Trial | active not recruiting | Phase 2 | 147 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT02688712 | ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer | active not recruiting | Phase 2 | 50 | Providence Health & ServicesOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04745988 | An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer | active not recruiting | Phase 2 | 43 | National Cancer Center Hospital EastOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05034887 | Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma | active not recruiting | Phase 2 | 64 | National Cancer Center Hospital EastOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT03916627 | Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients | active not recruiting | Phase 2 | 65 | Regeneron PharmaceuticalsINDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT03678883 | 9-ING-41 in Patients With Advanced Cancers | active not recruiting | Phase 2 | 350 | Actuate Therapeutics Inc.INDUSTRY | 7 | Apr 3, 2026 | clinicaltrials |
| NCT05318027 | ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy | active not recruiting | Phase 2 | 70 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT04963283 | Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer | active not recruiting | Phase 2 | 48 | University of Colorado, DenverOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT05622136 | Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma(STRAT-aHCC) | active not recruiting | Phase 2 | 28 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06178445 | Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer(TRAP-BTC) | active not recruiting | Phase 2 | 24 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT02758951 | Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases(CAIRO6) | active not recruiting | Phase 2 / Phase 3 | 358 | Koen RoversOTHER | 2 | Mar 24, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 1, 2026source: clinicaltrials